Our Lady of the Lake Cancer Institute announced its participation as the first site in Louisiana for a Phase I clinical trial evaluating allogeneic CAR-T cell therapy. Nakhle Saba, MD serves as the principal investigator for this study involving cellular immunotherapy. Allogeneic CAR-T therapy utilizes donor-derived T cells that are genetically engineered to recognize and target cancer cells. This approach may lead to reduced treatment durations and enhanced patient outcomes.
“Our participation in the clinical trial of this investigational treatment is a testament to our relentless pursuit of excellence in cancer care," said Nakhle Saba, MD. “We are thrilled to be at the forefront of providing access to such clinical trials for patients in the Gulf Region."
This latest work marks another important milestone for The Heme-Malignancy and Cell Therapy Program, which launched at Our Lady of the Lake Cancer Institute in September 2024 under the leadership of Susan Foret.